Crossmark

Open Innovation and Regulatory Challenges in New Modality Development: The Pivotal Role of Contract Development and Manufacturing Organisations in Advancing Antibody Drugs

Crossref DOI link: https://doi.org/10.1007/s43441-024-00701-x

Published Online: 2024-10-28

Published Print: 2025-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yoshiura, Hiromu

Kawata, Yayoi

Sengoku, Shintaro
Funding

Funding for this research was provided by:

Japan Society for the Promotion of Science (JSPS) and the Ministry of Education, Culture, Sports, Science and Technology (21H00739)
License Information

Text and Data Mining valid from 2024-10-28

Version of Record valid from 2024-10-28
More Information

Article History

Received: 23 March 2024

Accepted: 20 September 2024

First Online: 28 October 2024

Declarations

:

: The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Document is current

Any future updates will be listed below